157014-35-2

Basic information

• Product Name: 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE
• Synonyms: 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE;2-Bromo-2'-fluoro-4'-methoxyacetophenone, 2-Bromo-1-(2-fluoro-4-methoxyphenyl)ethan-1-one, 4-(Bromoacetyl)-3-fluoroanisole;2-BroMo-1-(2-fluoro-4-Methoxyphenyl)ethan-1-one;2-broMo-2'-fluoro-4'-Methoxyacetphenone;Ethanone, 2-bromo-1-(2-fluoro-4-methoxyphenyl)-;2-Fluoro-4-methoxyphenacylbromide97%
• CAS NO: 157014-35-2
• Molecular Formula: C₉H₈BrFO₂
• Molecular Weight: 247.07
• Mol File: 157014-35-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 293.6°C at 760 mmHg
• Flash Point: 131.3°C
• Appearance: /
• Density: 1.521g/cm³
• Vapor Pressure: 0.00171mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE(157014-35-2)
• EPA Substance Registry System: 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE(157014-35-2)

Safety Data

• Hazardous Substances Data: 157014-35-2(Hazardous Substances Data)

Usage

General Description

2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE is a chemical compound with the formula C9H8BrFO2. It is a ketone derivative that contains a bromine and a fluorine atom, as well as a methoxy group attached to a phenyl ring. 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE is commonly used in organic synthesis and can be used as a reagent in various chemical reactions. It is also used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. It has potential applications in medicinal chemistry and is of interest to researchers studying the biological activity of related compounds.

InChI:InChI=1/C9H8BrFO2/c1-13-6-2-3-7(8(11)4-6)9(12)5-10/h2-4H,5H2,1H3

Upstream product

• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 

Downstream Products

• 1403674-85-0 2,3,5-tris(2-fluoro-4-methoxyphenyl)-1-propyl-1H-pyrrole 
• 1403674-84-9 2,5-bis(2-fluoro-4-methoxyphenyl)-3-(4-methoxyphenyl)-1-propyl-1H-pyrrole 
• 1403674-83-8 2,5-bis(2-fluoro-4-methoxyphenyl)-3-(4-methoxyphenyl)-1-methyl-1H-pyrrole 
• 1403674-77-0 5-(2-fluoro-4-methoxyphenyl)-2,3-bis(4-methoxyphenyl)-1-propyl-1H-pyrrole 
• 1403674-76-9 5-(2-fluoro-4-methoxyphenyl)-2,3-bis(4-methoxyphenyl)-1-methyl-1H-pyrrole 
• 1403674-89-4 C₂₅H₂₂FNO₃ 
• 1403674-88-3 C₂₃H₁₈FNO₃ 
• 1403674-97-4 C₂₅H₂₀F₃NO₃ 
• 1403674-96-3 C₂₅H₂₁F₂NO₃ 
• 1403674-95-2 C₂₃H₁₇F₂NO₃ 
• 1403674-73-6 1,2,4-tris(2-fluoro-4-methoxyphenyl)-butane-1,4-dione 
• 1403674-70-3 4-(2-fluoro-4-methoxyphenyl)-1,2-bis(4-methoxyphenyl)-butane-1,4-dione 
• 1403674-72-5 1,4-bis(2-fluoro-4-methoxyphenyl)-2-(4-methoxyphenyl)butane-1,4-dione 
• 1314984-63-8 C₁₀H₉FN₂O 

Relevant articles and documents

NEGATIVE ALLOSTERIC MODULATION OF GLUN3-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS

Disclosed are negative allosteric modulators of GluN3-containing NMDA receptors. In general, these compounds are highly selective for GluN3 (such as GluN3A and/or GluN3B) over GluN1 and/or GluN2. They can function as non-competitive antagonists with activity that is independent of membrane potential, glycine concentration, and extracellular pH. Also disclosed are pharmaceutical formulations of the negative allosteric modulators. These compounds can be used to enhance synaptic function and/or treating a neurological condition or disorder. Exemplary neurological conditions or disorders include, but are not limited to, major mental disorders, conditions that involve basal ganglia or altered dopamine, substance abuse/addiction or predisposition to substance abuse/addiction, pain disorders, developmental delay or situations with impaired learning, memory, and/or cognition, acute neuronal or glial injuries, and circuit disorders.

Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain

A series of 2,4-diphenyl-1H-imidazole analogs have been synthesized and displayed potent human CB2 agonist activity. Many of these analogs showed high functional selectivity over human CB1 receptors. The syntheses, structure-activity relationships, and selected pharmacokinetic data of these analogs are described.

Process for producing optically active carbinols

The present invention relates to a process for producing optically active halomethyl phenyl carbinols of the formula (1), comprising reducing halomethyl phenyl ketones of the formula (2) using an asymmetric reducing agent obtained from boranes and optically active α-phenyl-substituted-β-amino alcohols of the formula (3) or optically active α-non-substituted-β-amino alcohols of the formula (4). The present invention further relates to a process for producing optically active carbinols, comprising reacting a prochiral keytone with an asymmetric reducing agent obtained from optically active β-amino alcohols of the formula (5), a metal boron hydride and Lewis acid or lower dialkyl sulfuric acid. All of the formulas (1) to (5) are the same as shown in the specification.